Inhibitory effects of miR-101 overexpression on cervical cancer SiHa cells

Purpose of investigation: microRNAs (miRNAs), which can regulate cell biological behaviors such as proliferation and apoptosis as oncogenes or anti-oncogenes, are closely associated with cancer onset and progression. The aim of this study was to detect the expression changes of miR-101 in cervical cancer tissues and the effects on the biological functions of cervical cancer SiHa cells. Materials and Methods: Through transient transfection of SiHa cells with mature miR-101 sequences, the effects on apoptosis, proliferation, and cell cycle were evaluated by real-time PCR, CCK-8 assay, and flow cytometry. Results: Significantly less miR-101 was expressed in cervical cancer tissues than that in normal cervical tissues. miR-101 was overexpressed in SiHa cells through transient transfection of miR-101 mimics. CCK-8 assay and flow cytometry showed that miR-101 overexpression significantly inhibited cell proliferation, promoted apoptosis, and arrested them in the G₁ /S phase. Real-time PCR exhibited that Mcl-1 and c-Fos mRNA expressions significantly decreased. Conclusion: miR-101 significantly reduced the viability of SiHa cells as a potential anti-oncogene.

[1] Wu L., Fan J., Belasco J.G.: “MicroRNAs direct rapid deadenylation of mRNA”. Proc. Natl. Acad. Sci. U S A, 2006, 103, 4034.

[2] Ying H.C., Xu H.Y., Lv J., Ying T.S., Yang Q.: “MicroRNA signatures of platinum-resistance in ovarian cancer”. Eur. J. Gynaecol. Oncol., 2015, 36, 16.

[3] Chan S.H., Wang L.H.: “Regulation of cancer metastasis by microRNAs”. J. Biomed. Sci., 2015, 22, 9.

[4] He L., Hannon G.J.: “MicroRNAs: small RNAs with a big role in gene regulation”. Nat. Rev. Genet., 2004, 5, 522.

[5] Mendell J.T.: “MicroRNAs: critical regulators of development, cellular physiology and malignancy”. Cell Cycle, 2005, 4, 1179.

[6] Iorio M.V., Croce C.M.: “MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review”. EMBO Mol. Med., 2012, 4, 143.

[7] Croce C.M.: “Causes and consequences of microRNA dysregulation in cancer”. Nat. Rev. Genet., 2009, 10, 704.

[8] Ferracin M., Veronese A., Negrini M.: “Micromarkers: miRNAs in cancer diagnosis and prognosis”. Expert Rev. Mol. Diagn., 2010, 10, 297.

[9] Han J., Huo M., Mu M., Liu J., Zhang J.: “[miR-497 suppresses proliferation of human cervical carcinoma HeLa cells by targeting cyclin E1]”. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2014, 30, 597.

[10] Hu X., Schwarz J.K., Lewis J.S., Jr., Huettner P.C., Rader J.S., Deasy J.O., et al.: “A microRNA expression signature for cervical cancer prognosis”. Cancer Res., 2010, 70, 1441.

[11] Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T., et al.: “Real-time quantification of microRNAs by stem-loop RT-PCR”. Nucleic Acids Res., 2005, 33, e179.

[12] Tsubokura M., Komatsu T., Kami M.: “The prevalence of high-risk human papillomavirus in women with different types of cervical cancer”. Ann. Intern. Med., 2008, 149, 283; author reply 283.

[13] Nuovo G.J., Wu X., Volinia S., Yan F., di Leva G., Chin N., et al.: “Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection”. Diagn. Mol. Pathol., 2010, 19, 135.

[14] Wang X., Tang S., Le S.Y., Lu R., Rader J.S., Meyers C., et al.: “Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth”. PLoS One, 2008, 3, e2557.

[15] Wan H.Y., Li Q.Q., Zhang Y., Tian W., Li Y.N., Liu M., et al.: “MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells”. Cancer Lett., 2014, 355, 148.

[16] Su H., Yang J.R., Xu T., Huang J., Xu L., Yuan Y., et al.: “MicroRNA- 101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity”. Cancer Res., 2009, 69, 1135.

[17] Li S., Fu H., Wang Y., Tie Y., Xing R., Zhu J., et al.: “MicroRNA- 101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma”. Hepatology, 2009, 49, 1194.

[18] Friedman J.M., Liang G., Liu C.C., Wolff E.M., Tsai Y.C., Ye W., et al.: “The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2”. Cancer Res., 2009, 69, 2623.

[19] Hiroki E., Akahira J., Suzuki F., Nagase S., Ito K., Suzuki T., et al.: “Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas”. Cancer Sci., 2010, 101, 241.

[20] Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., et al.: “Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer”. Science, 2008, 322, 1695.

[21] Allen T.D., Zhu C.Q., Jones K.D., Yanagawa N., Tsao M.S., Bishop J.M.: “Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer”. Cancer Res., 2011, 71, 2212.

[22] Schulze-Bergkamen H., Ehrenberg R., Hickmann L., Vick B., Urbanik T., Schimanski C.C., et al.: “Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells”. World J. Gastroenterol., 2008, 14, 3829.

[23] Toft D.J., Rosenberg S.B., Bergers G., Volpert O., Linzer D.I.: “Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression”. Proc. Natl. Acad. Sci. U S A, 2001, 98, 13055.

[24] Oliveira-Ferrer L., Rossler K., Haustein V., Schroder C., Wicklein D., Maltseva D., et al.: “c-FOS suppresses ovarian cancer progression by changing adhesion”. Br. J. Cancer, 2014, 110, 753.

[25] de Sousa S.O., Mesquita R.A., Pinto D.S., Jr., Gutkind S.: “Immunolocalization of c-Fos and c-Jun in human oral mucosa and in oral squamous cell carcinoma”. J. Oral Pathol. Med., 2002, 31, 78.

[26] Zhou L., He X.D., Yu J.C., Zhou R.L., Yang H., Qu Q., et al.: “Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro”. Am. J. Surg., 2010, 199, 515.